Detalles de la búsqueda
1.
Cognitive and psychiatric adverse events during adjunctive cenobamate treatment in phase 2 and phase 3 clinical studies.
Epilepsy Behav
; 151: 109605, 2024 Feb.
Artículo
Inglés
| MEDLINE | ID: mdl-38184949
2.
Failure to use new breakthrough treatments for epilepsy.
Epilepsia
; 64(6): 1458-1465, 2023 06.
Artículo
Inglés
| MEDLINE | ID: mdl-36855241
3.
Sublingual lorazepam as rescue therapy for seizure emergencies in adults.
Epilepsy Behav
; 145: 109294, 2023 08.
Artículo
Inglés
| MEDLINE | ID: mdl-37406555
4.
Future opportunities for research in rescue treatments.
Epilepsia
; 63 Suppl 1: S55-S68, 2022 09.
Artículo
Inglés
| MEDLINE | ID: mdl-35822912
5.
Seizure triggers identified postictally using a smart watch reporting system.
Epilepsy Behav
; 126: 108472, 2022 01.
Artículo
Inglés
| MEDLINE | ID: mdl-34942507
6.
Long-term safety of adjunctive cenobamate in patients with uncontrolled focal seizures: Open-label extension of a randomized clinical study.
Epilepsia
; 62(9): 2142-2150, 2021 09.
Artículo
Inglés
| MEDLINE | ID: mdl-34254673
7.
Post hoc analysis of a phase 3, multicenter, open-label study of cenobamate for treatment of uncontrolled focal seizures: Effects of dose adjustments of concomitant antiseizure medications.
Epilepsia
; 62(12): 3016-3028, 2021 12.
Artículo
Inglés
| MEDLINE | ID: mdl-34633074
8.
Efficacy of cenobamate for uncontrolled focal seizures: Post hoc analysis of a Phase 3, multicenter, open-label study.
Epilepsia
; 62(12): 3005-3015, 2021 12.
Artículo
Inglés
| MEDLINE | ID: mdl-34633084
9.
Cenobamate treatment of focal-onset seizures: Quality of life and outcome during up to eight years of treatment.
Epilepsy Behav
; 116: 107796, 2021 03.
Artículo
Inglés
| MEDLINE | ID: mdl-33567400
10.
Practical guidance for the management of adults receiving adjunctive cenobamate for the treatment of focal epilepsy-expert opinion.
Epilepsy Behav
; 123: 108270, 2021 10.
Artículo
Inglés
| MEDLINE | ID: mdl-34509033
11.
Assessment of the long-term efficacy and safety of adjunctive perampanel in tonic-clonic seizures: Analysis of four open-label extension studies.
Epilepsia
; 61(7): 1491-1502, 2020 07.
Artículo
Inglés
| MEDLINE | ID: mdl-32645213
12.
Late-onset epilepsy and 25-year cognitive change: The Atherosclerosis Risk in Communities (ARIC) study.
Epilepsia
; 61(8): 1764-1773, 2020 08.
Artículo
Inglés
| MEDLINE | ID: mdl-32710450
13.
Cenobamate (YKP3089) as adjunctive treatment for uncontrolled focal seizures in a large, phase 3, multicenter, open-label safety study.
Epilepsia
; 61(6): 1099-1108, 2020 06.
Artículo
Inglés
| MEDLINE | ID: mdl-32396252
14.
Postictal stertor: Associations with focal and bilateral seizure types.
Epilepsy Behav
; 110: 107103, 2020 09.
Artículo
Inglés
| MEDLINE | ID: mdl-32460174
15.
Antiepileptic drug withdrawal and seizure severity in the epilepsy monitoring unit.
Epilepsy Behav
; 109: 107128, 2020 08.
Artículo
Inglés
| MEDLINE | ID: mdl-32417383
16.
Strategies for non-EEG seizure detection and timing for alerting and interventions with tonic-clonic seizures.
Epilepsia
; 59 Suppl 1: 36-41, 2018 06.
Artículo
Inglés
| MEDLINE | ID: mdl-29873833
17.
Final safety, tolerability, and seizure outcomes in patients with focal epilepsy treated with adjunctive perampanel for up to 4 years in an open-label extension of phase III randomized trials: Study 307.
Epilepsia
; 59(4): 866-876, 2018 04.
Artículo
Inglés
| MEDLINE | ID: mdl-29574701
18.
Regulating drivers with epilepsy in Maryland: Results of the application of a United States consensus guideline.
Epilepsia
; 58(8): 1389-1397, 2017 08.
Artículo
Inglés
| MEDLINE | ID: mdl-28569419
19.
Perampanel for adjunctive treatment of partial-onset seizures: a pooled dose-response analysis of phase III studies.
Epilepsia
; 55(3): 423-31, 2014 Mar.
Artículo
Inglés
| MEDLINE | ID: mdl-24605793
20.
Long-term safety of perampanel and seizure outcomes in refractory partial-onset seizures and secondarily generalized seizures: results from phase III extension study 307.
Epilepsia
; 55(7): 1058-68, 2014 Jul.
Artículo
Inglés
| MEDLINE | ID: mdl-24867391